Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients.
BACKGROUND
Given that peginterferon-ribavirin treatment is poorly tolerated, there is interest in the identification of predictors of response, particularly in HIV/hepatitis C virus (HCV)-coinfected patients that respond less than HCV-monoinfected individuals. A single nucleotide polymorphism (SNP) near the IL28B gene (rs12979860) has been shown to predict treatment response in HCV-monoinfected patients carrying genotype 1. Information is lacking for HIV/HCV-coinfected individuals and/or other HCV genotypes.


METHODS
From 650 HIV/HCV-coinfected patients, we identified those who had completed a course of peginterferon-ribavirin therapy with a validated outcome and available repository DNA. The rs12979860 SNP was examined in a blinded fashion.


RESULTS
A total of 164 patients were included in the final IL28B genotyping analysis, 90 (55%) of whom achieved sustained virological response (SVR). HCV genotype distribution was as follows: HCV-1 58%, HCV-3 31% and HCV-4 11%. Overall, the SVR rate was higher in patients with CC than in those CT/TT genotypes: 56 of 75 (75%) versus 34 of 89 (38%) (P < 0.0001). The effect of the SNP was seen in HCV genotypes 1 and 4 but not in HCV genotype 3 carriers. In the multivariable analysis (odds ratio; 95% confidence interval; P value), the rs12979860 CC genotype was a strong predictor of SVR (3.7; 1.6-8.5; 0.002), independent of HCV genotype 3 (8.0; 3.1-21.0; <0.001), serum HCV-RNA less than 600,000 IU/ml (11.9; 3.8-37.4; <0.001) and lack of advanced liver fibrosis (3.5; 1.4-8.9; 0.009).


CONCLUSIONS
The rs12979860 SNP located near the IL28B gene is associated with HCV treatment response in HIV-infected patients with chronic hepatitis C due to genotypes 1 or 4. Thus, IL28B genotyping should be considered as part of the treatment decision algorithm in this difficult-to-treat population.
Rallón
Norma I
NI
Infectious Diseases Department, Hospital Carlos III, Madrid, Spain.
Naggie
Susanna
S
Benito
José M
JM
Medrano
José
J
Restrepo
Clara
C
Goldstein
David
D
Shianna
Kevin V
KV
Vispo
Eugenia
E
Thompson
Alex
A
McHutchison
John
J
Soriano
Vincent
V
D000328:Adult; D004359:Drug Therapy, Combination; D005260:Female; D005838:Genotype; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy / Q000235:genetics*; D016174:Hepacivirus / Q000235:genetics*; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy / Q000235:genetics*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D007372:Interferons; D007378:Interleukins / Q000235:genetics*; D008103:Liver Cirrhosis / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D012367:RNA, Viral; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use*; D012307:Risk Factors; D013030:Spain; D016896:Treatment Outcome; D000095022:Interferon Lambda
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D007372:Interferons; D007378:Interleukins; D011092:Polyethylene Glycols; D012367:RNA, Viral; D011994:Recombinant Proteins; D012254:Ribavirin; C000624353:interferon-lambda, human; D000095022:Interferon Lambda; C100416:peginterferon alfa-2a
J Hepatol. 2008 Oct;49(4):634-51
18715665
Clin Infect Dis. 2009 Apr 1;48(7):963-72
19236273
N Engl J Med. 2001 Jul 5;345(1):41-52
11439948
PLoS One. 2009 Dec 08;4(12):e8209
19997618
Hepatology. 2005 Jan;41(1):48-54
15690481
Nat Genet. 2009 Oct;41(10):1100-4
19749758
Hepatology. 2009 Apr;49(4):1335-74
19330875
Nature. 2009 Oct 8;461(7265):798-801
19759533
Gastroenterology. 2010 Apr;138(4):1338-45, 1345.e1-7
20060832
Clin Infect Dis. 2009 Nov 1;49(9):1397-401
19814621
Gastroenterology. 2005 Feb;128(2):343-50
15685546
Genet Anal. 1999 Feb;14(5-6):143-9
10084106
J Viral Hepat. 2011 May;18(5):325-30
20456635
Clin Infect Dis. 2004 Jan 1;38(1):128-33
14679458
Nature. 2009 Sep 17;461(7262):399-401
19684573
AIDS. 2007 May 31;21(9):1073-89
17502718
Gastroenterology. 2006 Dec;131(6):1887-98
17087946
Arch Intern Med. 2006 Aug 14-28;166(15):1632-41
16908797
J Acquir Immune Defic Syndr. 2006 Feb 1;41(2):175-9
16394849
Clin Infect Dis. 2001 Aug 15;33(4):562-9
11462196
Nat Immunol. 2003 Jan;4(1):69-77
12483210
Nat Genet. 2009 Oct;41(10):1105-9
19749757